Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Edith, Brutcher"'
Autor:
Amber Draper, Emily H. Jung, Yichun Cao, Rami P. Atallah, Jeffrey Switchenko, Sujata Kane, Jessica Guadagno, Aaron T. Jones, Edith Brutcher, Olatunji B. Alese
Publikováno v:
Oncology. 101:213-223
Introduction: Checkpoint inhibitors (CPI) have significantly improved survival among patients with various cancer types. Prior studies have shown a correlation between immune cell infiltration and poorly differentiated cancers. This study evaluated t
Autor:
Sujata, Kane, Edith, Brutcher, Jessica, Guadagno, Aaron, Jones, Sarah, Craven, Bassel F, El-Rayes
Publikováno v:
Pancreas. 51:e102-e103
Autor:
Lisa Weiss, Edith Brutcher, Yue-Yun To, Miao-Jen Wang, Sara Hamilton, Jane Koh, Hiu Tung Leung, Huanyu Zhao, Carmen Fuertes, Karen Julien, Megumi Mori, Holly DiFebo, Yun Shen, Aralee Galway, Marina Tschaika, Jocelyn Teo, Yoon Jin Noh
Publikováno v:
The Oncologist
Background CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment‐related adverse events (
Autor:
Gregory B. Lesinski, Ibrahim Halil Sahin, Sujata R. Kane, Clifford J. Gunthel, Jessica Guadagno, Edith Brutcher, Christina Wu, Bassel F. El-Rayes, Katherine Emilie Rhoades Smith
Publikováno v:
JCO Oncology Practice. 16:319-325
Recent studies have identified durable responses with the use of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC). The dramatic improvement
Publikováno v:
Journal of the Advanced Practitioner in Oncology
Pancreatic ductal adenocarcinoma remains a highly aggressive disease, with a 5-year relative survival rate of 10%. Numerous barriers to treatment exist, such as dense desmoplasia, infiltration of immune suppressor cells, inhibitory cytokines, low eff
Autor:
Christina Wu, Zhengjia Chen, Ganji Purnachandra Nagaraju, Chao Zhang, Walid L. Shaib, Edith Brutcher, Olatunji B. Alese, Meredith Renfroe, Hyun Soo Kim, Bassel F. El-Rayes
Publikováno v:
Cancer. 124:1992-2000
Background Neuroendocrine tumors (NETs) metastasize to the liver. Everolimus and selective internal radioembolization (SIRT) are approved treatments. Pasireotide is a somatostatin analogue with an affinity for somatostatin receptors 1, 2, 3, and 5. E
Autor:
Jean B. Sellers, Tahitia Timmons, Joanna Thompson, Edith Brutcher, Melissa Hennessey Smith, Judy B Koutlas, Deb Christensen
Publikováno v:
Clinical Journal of Oncology Nursing.
Background Uncommon early-onset severe toxicities from 5-fluorouracil (5-FU) and capecitabine can be fatal if early warning signs are not recognized and treated promptly. Objectives This article delineates the differences between expected side effect
Autor:
David A. Kooby, Richard J. Cassidy, Bassel F. El-Rayes, Zhengjia Chen, Shishir K. Maithel, Walid L. Shaib, Edith Brutcher, Juan M. Sarmiento, Chao Zhang, Natalyn Hawk, Jerome C. Landry
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 96:296-303
Purpose A challenge in borderline resectable pancreatic cancer (BRPC) management is the high rate of positive posterior margins (PM). Stereotactic body radiation therapy (SBRT) allows for higher radiation delivery dose with conformity. This study eva
Autor:
Lauren M. Postlewait, Volkan Adsay, Bassel F. El-Rayes, Cecilia G. Ethun, Zhengjia Chen, Charles A. Staley, Edith Brutcher, Juan M. Sarmiento, Shishir K. Maithel, David A. Kooby
Publikováno v:
Journal of Surgical Oncology. 114:336-341
Background Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO-001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P
Autor:
Walid L. Shaib, Edith Brutcher, Sungjin Kim, Jonathan Rock, Kavya Krishna, Zhengjia Chen, Michael Goodman, Samih Abdel-Missih, Shishir K. Maithel, Tanios Bekaii-Saab, Bassel F. El-Rayes, Charles Iii Staley
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Appendiceal tumors are a heterogeneous group of diseases that include typical neuroendocrine tumors (TNET), goblet cell carcinoids (GCC), and atypical GCC. Atypical GCC are classified into signet-ring cell cancers (SRCC) and poorly differenti